Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 1

3(37.5%)

N/A

2(25.0%)

8Total

Phase 3(3)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03671044Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Role: collaborator

NCT04315792Phase 3Completed

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Role: collaborator

NCT05419427Phase 3Unknown

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

Role: lead

NCT04258501Not ApplicableCompleted

Exploratory Study of Efficacy on Selected Natural Extracts Reducing Post Prandial Blood Glucose Response

Role: collaborator

NCT04256746Not ApplicableCompleted

Dose Response Study of a Natural Extract for Reducing Post Prandial Blood Glucose

Role: collaborator

NCT03681548Phase 1Completed

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Role: collaborator

NCT04015232Phase 1Completed

Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Role: collaborator

NCT04014062Phase 1Completed

Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Role: collaborator

All 8 trials loaded